ライフサイエンスコーパス: 5'-nucleotidase

1 AP suppresses pain by functioning as an ecto-5'-nucleotidase.

2 is mediated by selective inhibition of ecto-5'-nucleotidase.

3 or potential targets of zinc other than ecto-5'-nucleotidase.

4 ptor agonists or reconstitution with soluble 5'-nucleotidase.

5 l actions of ecto-phosphodiesterase and ecto-5'-nucleotidase.

6 ted with inhibition of SAH hydrolase but not 5'-nucleotidase.

7 dforward ADP-mediated inhibition of the ecto-5'-nucleotidase.

8 ) were all significantly reduced by blocking 5'-nucleotidase.

9 by P-O bond cleavage by phosphatases such as 5'-nucleotidase.

10 utations in the same gene, NT5C2, encoding a 5'-nucleotidase.

11 s specifically blocked by parasite secretory 5'-nucleotidase.

12 d from ischemic neurologic injury by soluble 5'-nucleotidase.

13 enuated by treatment of WT mice with soluble 5'-nucleotidase.

14 t description of autoantibodies to cytosolic 5' nucleotidase 1A in patients with IBM is a potentially

15 nalysis revealed that Mup44 is the cytosolic 5'-nucleotidase 1A (cN1A).

16 e entire human proteome identified cytosolic 5'-nucleotidase 1A (cN1A; NT5C1A) as the likely 43 kDa I

17 Serum autoantibodies against cytosolic 5'-nucleotidase 1A have been identified in IBM showing m

18 antibodies against the GPI-anchored protein 5' nucleotidase (5' NT) at the apical membrane of MDCK c

19 5' nucleotidase (5'N) is a major source of the vasogenic

20 new method for microassay of the activity of 5'-nucleotidase (5'-ND) and adenosine deaminase (ADA) in

21 We demonstrate that soluble 5'-nucleotidase (5'-NT) and alkaline phosphatase (AP) me

22 The adenosine producing enzyme ecto-5'-nucleotidase (5'-NT) is not normally expressed during

23 cluster of differentiation (CD)39] and ecto-5'-nucleotidase (5'-NT; CD73), among others.

24 e that purified, recombinant human cytosolic 5'-nucleotidases (5'-NTs) CN-II and CN-III, but not CN-I

25 (such as carboxylesterase), and PM (such as 5'-nucleotidase [5'-ND]; alkaline phosphatase [AP]; and

26 and enzymatic activity assays indicated that 5'-nucleotidase (5NT), rather than AP, was responsible f

27 ulence factor, which we termed streptococcal 5'-nucleotidase A (S5nA).

28 1A30 recombinant protein cofractionated with 5'-nucleotidase, a classical GPI-anchored membrane marke

29 These estradiol binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and ar

30 3 wk) elevated plasma zinc and activities of 5'-nucleotidase, a zinc-dependant enzyme, in 20 postmeno

31 not aminopeptidase N, aminopeptidase P, and 5'-nucleotidase activities.

32 We show that cNIII-like also displays 5' nucleotidase activity with a high affinity for m(7)GM

33 e identified a novel S. pyogenes enzyme with 5'-nucleotidase activity and immune evasion properties.

34 compounds induced a strong inhibition of the 5'-nucleotidase activity in vitro, and the most potent o

35 enzymes possess nicotinamide mononucleotide 5'-nucleotidase activity in vitro.

36 These results not only show that ecto-5'-nucleotidase activity is a critical mediator of metho

37 The NudP ecto-5'-nucleotidase activity is reminiscent of the reactions

38 Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP breakdown

39 binant NudP revealed a Mn(2+)-dependent ecto-5'-nucleotidase activity on ribo- and deoxyribonucleosid

40 In COS-7 cells, 5'-nucleotidase activity was not rate-limiting for inosi

41 In H9c2 cells, in which 5'-nucleotidase activity was rate-limiting, only cN-II o

42 hate kinase (Ndk), adenylate kinase (Ak) and 5'-nucleotidase activity, the level of secretion of the

43 c supplementation doubled the mean value for 5'-nucleotidase activity, values were still significantl

44 ree thyroxine concentrations and mononuclear 5'-nucleotidase activity.

45 the recombinant and native proteins possess 5'-nucleotidase activity; hence, the protein has been ca

46 a Mono Q column demonstrates the presence of 5'-nucleotidase, adenylate kinase, and a putative ATP re

47 -methylene-ADP, often used to block the ecto-5'-nucleotidase, also inhibited voltage-gated K(+) curre

48 acking A2A adenosine receptor (A2AR) or ecto-5'nucleotidase (an enzyme that converts extracellular AM

49 study tested the hypothesis that CD73 (ecto-5'nucleotidase), an enzyme that catalyzes the conversion

50 lipid rafts marked by GPI-anchored proteins (5' nucleotidase and folate receptor).

51 tion of the apical plasma membrane proteins, 5'-nucleotidase and aminopeptidase N in lysosomal vacuol

52 and inosine monophosphate-specific cytosolic 5'-nucleotidase and an elevation of ecto-5'-nucleotidase

53 at NKT cells express both CD39 and CD73/ecto-5'-nucleotidase and can therefore generate adenosine fro

54 SNPs at the 5'-nucleotidase and xanthine oxidase genes influence the

55 dase activity, the level of secretion of the 5'-nucleotidase (and/or ATPase/phosphatase) appears to b

56 nstrate nucleoside diphosphate kinase (Ndk), 5' nucleotidase, and adenylate kinase (Ak) activities.

57 the following secreted exoenzymes: apyrase, 5'-nucleotidase, and adenosine deaminase.

58 m, adenosine is generated by the enzyme ecto-5'-nucleotidase, and adenosine production and adenosine

59 hate kinase (Ndk), ATPase, adenylate kinase, 5'-nucleotidase, and ATP-modifying enzymatic activities.

60 tein phosphatases, purple acid phosphatases, 5'-nucleotidase, and DNA repair enzymes such as Mre11.

61 tase, protein serine/threonine phosphatases, 5'-nucleotidase, and DNA repair enzymes such as Mre11.

62 ibroblast-like cells (e.g., collagen I, ecto-5'-nucleotidase, and PDGF receptor-beta).

63 sn1, initially classified as an IMP-specific 5'-nucleotidase, and Sdt1, initially classified as a pyr

64 The apical PM proteins aminopeptidase N, 5'nucleotidase, and the polymeric IgA receptor were effi

65 ot with this solution plus a blocker of ecto-5'-nucleotidase (AOPCP).

66 d Sdt1, initially classified as a pyrimidine 5'-nucleotidase, are additionally responsible for dephos

67 A 5'-nucleotidase, as well as hyaluronidase activity, was

68 l muscle fibres and dephosphorylated by ecto 5'nucleotidase bound to the sarcolemma.

69 pression of mRNAs for ENPP1, NTPD1, and ecto-5'-nucleotidase, but not NTPD2 (ecto-ATPase, or CD39L1),

70 in the supernate of cells deficient in ecto-5'-nucleotidase, but there is a marked increase in extra

71 acellular adenosine as generated by the ecto-5'-nucleotidase CD73 in fibrosis development after thora

72 rates AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine.

73 An inhibitor of the ecto-5'-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP),

74 e immunosuppressive cell surface enzyme ecto-5'-nucleotidase CD73.

75 adenosine monophosphate [AMP]) and CD73 ecto-5'-nucleotidase (CD73 converts AMP to adenosine).

76 as "Treg") express apyrases (CD39) and ecto-5'-nucleotidase (CD73) and contribute to their inhibitor

77 lective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1.

78 lized to adenosine by surface-expressed ecto-5'-nucleotidase (CD73) and subsequently activates surfac

79 Ecto-5'-nucleotidase (CD73) catalyzes the terminal phosphohyd

80 Because ecto-5'-nucleotidase (CD73) catalyzes the terminal step in ex

81 ction of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial barrie

82 taining, we confirmed the expression of ecto-5'-nucleotidase (CD73) in trigeminal nociceptive neurons

83 We show that inhibition of ecto-5'-nucleotidase (CD73) in vitro reduces carotid body bas

84 Ecto-5'-nucleotidase (CD73) is a central surface enzyme gener

85 Subsequently, we determined that ecto-5'-nucleotidase (CD73) is a key enzyme required for the

86 Ecto-5'-nucleotidase (CD73) is central to the generation of e

87 Ecto-5'-nucleotidase (CD73) is expressed abundantly on the ap

88 Ecto-5'-nucleotidase (CD73) is the main enzyme responsible fo

89 Nucleotide phosphohydrolysis by the ecto-5'-nucleotidase (CD73) is the main source for extracellu

90 nism, K8/K18 accumulation and increased ecto-5'-nucleotidase (CD73) levels were noted.

91 Ecto-5'-nucleotidase (CD73) on immune cells is emerging as a

92 tory response, we evaluated the role of ecto-5'-nucleotidase (CD73) on the development of heart failu

93 39) to AMP, which then is hydrolyzed by ecto-5'-nucleotidase (CD73) to adenosine.

94 In addition, increased activity of ecto-5'-nucleotidase (CD73) was found in the lungs in conjunc

95 ate (ATP) diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73) were increased twofold to threefo

96 1 than in the DG, and concentrations of ecto-5'-nucleotidase (CD73) were much higher in CA1.

97 Levels of ecto-5'-nucleotidase (CD73), an enzyme that converts extracel

98 The present study investigated whether ecto-5'-nucleotidase (CD73), an enzyme that generates adenosi

99 Ecto-5'-nucleotidase (CD73), encoded by NT5E, is the major en

100 of the adenosine-generating ectoenzyme, ecto-5'-nucleotidase (CD73), in regulating immune and organ f

101 We investigated whether ecto-5'-nucleotidase (CD73), the "pacemaker" enzyme of extrac

102 Ecto-5'-nucleotidase (CD73), the enzyme that generates adenos

103 We now show that ecto-5'-nucleotidase (CD73), the major enzyme able to convert

104 -monophosphate (AMP) through the enzyme ecto-5'-nucleotidase (CD73), we examined the contribution of

105 ity of the adenosine-generating enzyme, ecto-5'-nucleotidase (CD73), which was significantly lower in

106 he terminal enzymatic step catalyzed by ecto-5'-nucleotidase (CD73).

107 phosphate diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73).

108 back) in mice with targeted deletion of ecto-5'-nucleotidase/CD73 (e-5'NT/CD73), the enzyme responsib

109 sphate diphosphohydrolase (NTPDase) and ecto-5'-nucleotidase/CD73 activities in thoracic aortas, lymp

110 iphosphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities were measured in 226 pat

111 ated several structural modifications of the 5'-nucleotidase cDNA, expressed the corresponding protei

112 ed and characterized a novel human cytosolic 5'-nucleotidase (cN-I) that potentially may have an impo

113 Messenger RNA for the cytosolic AMP-specific 5'-nucleotidase (CN-I) was not detected in human bronchi

114 Two, cloned cytosolic 5'-nucleotidases (cN-I and cN-II) have been implicated i

115 now been identified as targeting cytoplasmic 5' nucleotidase (cN1A; NT5C1A), a protein involved in nu

116 This indicates that the 5'-nucleotidase contributes to but is not solely respons

117 e purine metabolism (inosine triphosphatase, 5'-nucleotidase cytosolic-II, purine nucleoside phosphor

118 for both hemoglobin E (Hb E) and pyrimidine 5' nucleotidase deficiency are segregating.

119 ptomatic and those homozygous for pyrimidine 5' nucleotidase deficiency have the mild hemolytic anemi

120 hat the hemolysis associated with pyrimidine 5' nucleotidase deficiency results not only from an incr

121 rease in the stability of Hb E in pyrimidine 5' nucleotidase-deficient red blood cells (RBCs).

122 Wild type, ecto-5'-nucleotidase-deficient, and adenosine receptor-defici

123 c stimuli are paired with disruption of ecto-5'-nucleotidase-dependent adenosine production or A1-ade

124 ion of CD39/ENTPD1 in concert with CD73/ecto-5'-nucleotidase distinguishes CD4(+)/CD25(+)/Foxp3(+) T

125 potent against c-N-I than the membrane ecto-5'-nucleotidase (e-N).

126 IMP-specific, High Km 5'-nucleotidase (EC 3.1.3.5) is an ubiquitous enzyme, th

127 ted the conversion of AMP to adenosine: ecto 5'-nucleotidase (ecto 5'-NT, CD73) and alkaline phosphat

128 lic 5'-nucleotidase and an elevation of ecto-5'-nucleotidase (ecto-5'-NT).

129 We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-bound met

130 ividuals, siRNA of tetraspanin 33 (TSPAN33), 5'-nucleotidase, ecto (NT5E), transmembrane emp24 protei

131 ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of e

132 h) cells correlated with high levels of ecto-5'-nucleotidase enzymatic activity.

133 ucleotidase II gene (NT5C2), which encodes a 5'-nucleotidase enzyme that is responsible for the inact

134 subset had the highest levels of CD73 (ecto-5'-nucleotidase) expression (Deltamean fluorescence inte

135 strong in salivary-expressed members of the 5'-nucleotidase family of arthropods because of constrai

136 Members of the 5'nucleotidase family were recruited for salivary expres

137 l, while release of AMP and affinity of ecto 5'nucleotidase for AMP are increased by acidosis.

138 Here we describe a novel 5' nucleotidase from Drosophila that cleaves m(7)GMP to

139 led to the redistribution of syntaxin 2 and 5' nucleotidase from the apical membrane to subapical pu

140 Two SNPs at the 5'-nucleotidase gene were associated with NCPH: rs111915

141 MP-CP), and a competitive substrate for ecto-5'-nucleotidase (guanosine monophosphate, GMP) did not a

142 However, inhibition of 5'-nucleotidase had no effect on ATP/ADP/UTP-induced pho

143 HUVEC express NTPDases, as well as 5'-nucleotidase; hence, nucleotides can be metabolized t

144 used to develop inhibitors of the cytosolic 5'-nucleotidase I (c-N-I) from myocardium.

145 design potential inhibitors of the cytosolic 5'-nucleotidase II (cN-II), which has been recognized as

146 cing, we identify mutations in the cytosolic 5'-nucleotidase II gene (NT5C2), which encodes a 5'-nucl

147 ng ABL1 fusions, NOTCH1/FBXW7, and cytosolic 5'-nucleotidase II gene mutations identify patient group

148 e potent inhibiting c-N-I than the cytosolic 5'-nucleotidase II.

149 Cytosolic 5'-nucleotidase III (cN-III) is responsible for selectiv

150 is supported by comparison to YfdR, another 5'-nucleotidase in E. coli.

151 the role of adenosine generated by CD73/ecto-5'-nucleotidase in GVHD.

152 Zinc was a less potent inhibitor of ecto-5'-nucleotidase in vitro than the nucleotide analog alph

153 directly studied the properties of the ecto-5'-nucleotidase in Xenopus embryo spinal cord.

154 Both parasite secreted products and the 5'-nucleotidase inhibit ADP-induced release of mast cell

155 Because ecto 5' nucleotidase inhibitor (alpha,beta-methylene adenosin

156 ted cells to activated neutrophils; the ecto-5'-nucleotidase inhibitor alpha, beta-methylene adenosin

157 ent beads was inhibited by ATP, but the ecto-5'-nucleotidase inhibitor alpha, beta-methylene ADP prev

158 Addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP (200

159 was greatly reduced by addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP (200

160 The ecto-5'-nucleotidase inhibitor alphabeta-meADP significantly

161 0.4 +/- 2.8%, while AOPCP (12.5 mm), an ecto-5'-nucleotidase inhibitor that increases extracellular A

162 adenosine activity was clamped by combining 5'-nucleotidase inhibitor with A1-agonist to determine w

163 nflammation, and injection of APCP, the ecto-5'-nucleotidase inhibitor, abrogates completely the incr

164 enosine using a combination of a potent ecto-5'-nucleotidase inhibitor, alpha,beta-methylene adenosin

165 denosine A1 receptor blocker, A1-agonist, or 5'-nucleotidase inhibitor.

166 de transporter inhibitor; APCP, a CD73 (ecto-5'-nucleotidase) inhibitor; or cold adenosine significan

167 EPEC infection by testing the effect of ecto-5'-nucleotidase inhibitors.

168 CD73/ecto-5'-nucleotidase is an enzyme that generates adenosine, w

169 ves the PO4 moieties from ATP, likely with a 5'-nucleotidase-like enzyme rather than alkaline phospha

170 We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established th

171 Use of soluble 5'-nucleotidase may be a potential therapeutic for hepat

172 During exercise, the concentration of ecto 5'nucleotidase may be increased by translocation from th

173 vidence that adenosine results from the ecto-5'-nucleotidase- mediated conversion of adenine nucleoti

174 Such fractions, harboring 5' nucleotidase, Ndk, and presumably other ATP-utilizing

175 up B Streptococcus expresses a specific ecto-5'-nucleotidase necessary for its pathogenicity and high

176 that specific NTPDases, in tandem with ecto-5'-nucleotidase, not only terminate P2 receptor activati

177 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidase (NT5E) hydrolyze extracellular AMP to ad

178 Thereby, we demonstrate that ecto-5'-nucleotidase (NT5e) is specifically expressed in STP

179 Ecto-5'-nucleotidase (NT5E, CD73) is a membrane-anchored prot

180 (2B)R) after hydrolysis to adenosine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phosphata

181 stimulation mainly by the action of the ecto-5'-nucleotidase, NT5E, and to a lesser extent, prostatic

182 riglyceride content, while mice lacking ecto-5'-nucleotidase or adenosine A1 or A2B receptors were pr

183 he bed bug Cimex lectularius apyrase, (ii) a 5'-nucleotidase/phosphodiesterase, (iii) a hyaluronidase

184 In this study, we show that CD73 (ecto-5'-nucleotidase) plays an important role in regulating t

185 at target the cell-surface enzyme CD73 (ecto-5'-nucleotidase) reduce growth of primary tumors and met

186 econstitution of cd73(-/-) mice with soluble 5'-nucleotidase resulted in complete restoration of hepa

187 Mutations in ushA, encoding a predicted 5'-nucleotidase, resulted in accumulation of flavin aden

188 Like other 5'-nucleotidases, S5nA requires divalent cations and was

189 thway (transformation of AMP to adenosine by 5'-nucleotidase) seems to be the rate-limiting step.

190 ified a cell wall-anchored protein harbors a 5'-nucleotidase signature sequence and evidence strongly

191 ntly facilitated in the presence of the ecto-5'-nucleotidase substrate 5'-AMP.

192 e process of association and dissociation of 5'-nucleotidase subunits.

193 CD73 is an ecto-5' nucleotidase that catalyzes the terminal phosphohydro

194 n by the upstream metabolite ADP of the ecto-5'-nucleotidase that converts AMP to adenosine introduce

195 mice that lack the CD73 gene (encoding ecto-5'-nucleotidase that converts AMP to adenosine) to test

196 CD73 is a cell surface 5'-nucleotidase that converts AMP to adenosine, an immun

197 lectivity for c-N-I versus both of the other 5'-nucleotidases, the nucleoside inhibitors of c-N-I may

198 Eukaryotic pyrimidine 5'-nucleotidase type 1 (P5N-1) catalyzes dephosphorylati

199 or treatment of wild-type mice with soluble 5'-nucleotidase was associated with significantly lower

200 However, the activity of cytosolic 5'-nucleotidase was elevated 6- to 10-fold.

201 The secreted 5'-nucleotidase was identified as a protein with an appa

202 glycophosphatidylinositol-anchored protein, 5'-nucleotidase, were observed, suggesting that increase

203 y degraded into adenosine by ecto-ATPase and 5'-nucleotidase, which have been identified in the canal

204 omain phosphohydrolase, the Escherichia coli 5'-nucleotidase YfbR.

205 ases (ndk, pykA, or pykF) and the gene for a 5'-nucleotidase (yfbR).